Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1

Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study

Published:2022-10 Issue:10 Volume:9 Page:e756-e765
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Bazinet Alexandre,Darbaniyan Faezeh,Jabbour Elias,Montalban-Bravo Guillermo,Ohanian Maro,Chien Kelly,Kadia Tapan,Takahashi Koichi,Masarova Lucia,Short Nicholas,Alvarado Yesid,Yilmaz Musa,Ravandi Farhad,Andreeff Michael,Kanagal-Shamanna Rashmi,Ganan-Gomez Irene,Colla Simona,Qiao Wei,Huang Xuelin,McCue Deborah,Mirabella Bailey,Kantarjian Hagop,Garcia-Manero Guillermo

Publisher

Elsevier BV

Subject

Hematology

Reference28 articles.

1. Myelodysplastic syndromes;Cazzola;N Engl J Med,2020

2. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

3. Revised international prognostic scoring system for myelodysplastic syndromes;Greenberg;Blood,2012

4. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

5. Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes;Seminars in Hematology;2024-08

3. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN;Leukemia Research;2024-07

4. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee;Blood;2024-05-30

5. Advances in the management of higher-risk myelodysplastic syndromes: future prospects;Leukemia & Lymphoma;2024-05-07